Skip navigation

DAY ONE Wednesday, June 19, 2019

7:30

Registration and Continental Breakfast

8:30

Chairman’s Welcome and Opening Remarks

Robert Popovian, PharmD, MS
Vice President, U.S. Government Relations
Pfizer Inc

8:45

KEYNOTE ADDRESS
Washington Update on Medicare Policy

Abe Sutton
Health Advisor at Domestic Policy Council
The White House

9:30

What’s Next for Medicare? — Perspective From Capitol Hill

J.P. Paluskiewicz
Chief Minority Health Counsel, Energy & Commerce Committee
US House of Representatives

10:15

Networking and Refreshment Break

10:45

Insights from an Actuary on Changes to Medicare Part D

David Mike, FSA, MAAA
Consulting Actuary
Milliman

Katie Holcomb, FSA, MAAA
Consulting Actuary
Milliman

11:30

Evaluate Reimbursement and Value-Based Payment Initiatives

Terrill Jordan
President and CEO
Regional Cancer Care Associates

12:15

Networking Luncheon

1:15

International Pricing Index Model —
Evaluate the Proposed Changes for Medicare Part B Drugs

Tara O’Neill Hayes
Deputy Director of Health Care Policy
American Action Forum

Wayne Winegarden, PhD
Senior Fellow
Pacific Research Institute

2:15

Impact of Value Frameworks on Access to Medications

Robert Popovian, PharmD, MS
Vice President, U.S. Government Relations
Pfizer Inc

3:00

Networking and Refreshment Break

3:30

Examine the Implementation Strategies for Step Therapy Under
Medicare Part B

Milena Sullivan
Principal
Avalere Health

4:15

Assess the Future of Medicare Part D

Alison Anway
Principal
Anway Long Group

Douglas Holtz-Eakin
President
American Action Forum

5:00

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO Thursday, June 20, 2019

7:30

Registration and Continental Breakfast

8:00

Chairman’s Review of Day One

Robert Popovian, PharmD, MS
Vice President, U.S. Government Relations
Pfizer Inc

8:15

Medicare Part D v2.0

Mike Anderson
Chief Executive Officer, Part D
UnitedHealthcare

9:00

PANEL DISCUSSION
Discover Coverage and Payment Strategies for Novel and
High Cost Therapies for Rare Diseases Under Medicare Parts A and B

MODERATOR:

Michael Eging
Executive Director
Rare Access Action Project

PANELISTS:

Robert Falb
Director, U.S. Policy & Advocacy
Alliance for Regenerative Medicine

James Wu, M.Sc., M.P.H.
Principal Health Economist, HTA Center of Excellence
Amgen, Inc.

10:00

Networking and Refreshment Break

10:30

PANEL DISCUSSION
Review the Future of Part D’s Six Protected Drug Classes

MODERATOR:

Lisa Kennedy, PhD
Managing Principal
Innopiphany LLC

PANELISTS:

Nicole Braccio, PharmD
Policy Director
National Patient Advocate Foundation

Surya Singh, MD
President, Singh Healthcare Advisors, LLC;
former VP/CMO, CVS Health Specialty

11:30

Update on Proposed Changes to Medicare and Medicaid

Arielle Kane
Director of Health Care
Progressive Policy Institute

12:15

Close of Conference

Want more agenda details? Download the brochure.

DAY ONE Wednesday, June 19, 2019

7:30

Registration and Continental Breakfast

8:30

Chairman’s Welcome and Opening Remarks

Robert Popovian, PharmD, MS
Vice President, U.S. Government Relations
Pfizer Inc

8:45

KEYNOTE ADDRESS
Washington Update on Medicare Policy

Abe Sutton
Health Advisor at Domestic Policy Council
The White House

9:30

What’s Next for Medicare? — Perspective From Capitol Hill

J.P. Paluskiewicz
Chief Minority Health Counsel, Energy & Commerce Committee
US House of Representatives

10:15

Networking and Refreshment Break

10:45

Insights from an Actuary on Changes to Medicare Part D

David Mike, FSA, MAAA
Consulting Actuary
Milliman

Katie Holcomb, FSA, MAAA
Consulting Actuary
Milliman

11:30

Evaluate Reimbursement and Value-Based Payment Initiatives

Terrill Jordan
President and CEO
Regional Cancer Care Associates

12:15

Networking Luncheon

1:15

International Pricing Index Model —
Evaluate the Proposed Changes for Medicare Part B Drugs

Tara O’Neill Hayes
Deputy Director of Health Care Policy
American Action Forum

Wayne Winegarden, PhD
Senior Fellow
Pacific Research Institute

2:15

Impact of Value Frameworks on Access to Medications

Robert Popovian, PharmD, MS
Vice President, U.S. Government Relations
Pfizer Inc

3:00

Networking and Refreshment Break

3:30

Examine the Implementation Strategies for Step Therapy Under
Medicare Part B

Milena Sullivan
Principal
Avalere Health

4:15

Assess the Future of Medicare Part D

Alison Anway
Principal
Anway Long Group

Douglas Holtz-Eakin
President
American Action Forum

5:00

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO Thursday, June 20, 2019

7:30

Registration and Continental Breakfast

8:00

Chairman’s Review of Day One

Robert Popovian, PharmD, MS
Vice President, U.S. Government Relations
Pfizer Inc

8:15

Medicare Part D v2.0

Mike Anderson
Chief Executive Officer, Part D
UnitedHealthcare

9:00

PANEL DISCUSSION
Discover Coverage and Payment Strategies for Novel and
High Cost Therapies for Rare Diseases Under Medicare Parts A and B

MODERATOR:

Michael Eging
Executive Director
Rare Access Action Project

PANELISTS:

Robert Falb
Director, U.S. Policy & Advocacy
Alliance for Regenerative Medicine

James Wu, M.Sc., M.P.H.
Principal Health Economist, HTA Center of Excellence
Amgen, Inc.

10:00

Networking and Refreshment Break

10:30

PANEL DISCUSSION
Review the Future of Part D’s Six Protected Drug Classes

MODERATOR:

Lisa Kennedy, PhD
Managing Principal
Innopiphany LLC

PANELISTS:

Nicole Braccio, PharmD
Policy Director
National Patient Advocate Foundation

Surya Singh, MD
President, Singh Healthcare Advisors, LLC;
former VP/CMO, CVS Health Specialty

11:30

Update on Proposed Changes to Medicare and Medicaid

Arielle Kane
Director of Health Care
Progressive Policy Institute

12:15

Close of Conference